Many patients with severe COVID-19 who received daily infusions of Gilead Sciences' antiviral drug remdesivir experienced rapid recoveries, and almost all were discharged in less than one week, according to infectious disease specialist Kathleen Mullane, who is supervising the research at the University of Chicago Medicine. The comments were made during an internal presentation, and the institution said "drawing any conclusions at this point is premature and scientifically unsound."
Early data: Remdesivir may aid COVID-19 recovery
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.